- Email: [email protected]
5594101 Anti-obesity proteins
PATENT ABSTRACTS
stable effect. Furthermore, the sustained-release preparation does not show excess drug release just after administration.
781
(deglucoteicoplanin) and its salts with bases and acids by submitting a teicoplanin compound or a teicoplanin-like compound to controlled strong acid hydrolysis in the presence of an organic aprotic solvent, and a purification thereof.
5594100 EPITOPE FOR P R E V E N T I O N OF TYPE I DIABETES Wegmann Dale R Denver, CO, UNITED STATES Assigned to Regents of the University of Colorado The present invention encompasses peptides derived from the 15 residue peptide 9-23, Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys -Gly-Glu-Arg-Gly (SEQ ID NO:l), of the B chain of insulin. Peptides of the present invention are capable of acting as tolerogens for preventing type I diabetes.
5594104 ANTI-OBESITY PROTEINS Basinski Margret B; DiMarchi Richard D; Flora David B; Heath William F; Hoffmann James; Schoner Brigitte E; Shields James E; Smiley David L Indianapolis, IN, UNITED STATES Assigned to Eli Lilly and Company The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
5594101 ANTI-OBESITY PROTEINS
5594105
Becker Gerald W; Hale John; MacKellar Warren Fishers, IN, UNITED STATES Assigned to Eli Lilly and Company
PEPTIDE INHIBITORS OF MITOGENESIS AND MOTOGENESIS
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type I1 diabetes, cardiovascular disease and cancer.
Comoglio Paolo; Ponzetto Carola Turin, ITALY Assigned to Farmitalia Carlo Erba S r I
5594102 C H E M I C A L PROCESS FOR P R E P A R I N G ANTIBIOTIC L 17932 (DEGLUCOTEICOPLANIN) AND ITS SALT Panzone Giambattist; Gianantonio Anaclet Comaredo, ITALY Assigned to Gruppo Lepetit S pA The present invention is directed to a chemical process for preparing antibiotic L 17392
The invention in the field of cell biology relates to novel peptides able to interact with intracellular signal transducers, thus interfering with signal transduction pathways leading to cell proliferation and motility. The peptides of the invention may be chemically synthesized from single amino acids and/or preformed peptides of two or more amino acid residues. The peptides of the invention find an useful application in the treatment of a neoplastic disease.
5594106 INHIBITORS OF TNF- A L P H A SECRETION Black Roy A; Fitzner Jeffrey N; Sleath Paul Seattle, WA, UNITED STATES Assigned to Immunex Corporation
stable effect. Furthermore, the sustained-release preparation does not show excess drug release just after administration.
781
(deglucoteicoplanin) and its salts with bases and acids by submitting a teicoplanin compound or a teicoplanin-like compound to controlled strong acid hydrolysis in the presence of an organic aprotic solvent, and a purification thereof.
5594100 EPITOPE FOR P R E V E N T I O N OF TYPE I DIABETES Wegmann Dale R Denver, CO, UNITED STATES Assigned to Regents of the University of Colorado The present invention encompasses peptides derived from the 15 residue peptide 9-23, Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys -Gly-Glu-Arg-Gly (SEQ ID NO:l), of the B chain of insulin. Peptides of the present invention are capable of acting as tolerogens for preventing type I diabetes.
5594104 ANTI-OBESITY PROTEINS Basinski Margret B; DiMarchi Richard D; Flora David B; Heath William F; Hoffmann James; Schoner Brigitte E; Shields James E; Smiley David L Indianapolis, IN, UNITED STATES Assigned to Eli Lilly and Company The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
5594101 ANTI-OBESITY PROTEINS
5594105
Becker Gerald W; Hale John; MacKellar Warren Fishers, IN, UNITED STATES Assigned to Eli Lilly and Company
PEPTIDE INHIBITORS OF MITOGENESIS AND MOTOGENESIS
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type I1 diabetes, cardiovascular disease and cancer.
Comoglio Paolo; Ponzetto Carola Turin, ITALY Assigned to Farmitalia Carlo Erba S r I
5594102 C H E M I C A L PROCESS FOR P R E P A R I N G ANTIBIOTIC L 17932 (DEGLUCOTEICOPLANIN) AND ITS SALT Panzone Giambattist; Gianantonio Anaclet Comaredo, ITALY Assigned to Gruppo Lepetit S pA The present invention is directed to a chemical process for preparing antibiotic L 17392
The invention in the field of cell biology relates to novel peptides able to interact with intracellular signal transducers, thus interfering with signal transduction pathways leading to cell proliferation and motility. The peptides of the invention may be chemically synthesized from single amino acids and/or preformed peptides of two or more amino acid residues. The peptides of the invention find an useful application in the treatment of a neoplastic disease.
5594106 INHIBITORS OF TNF- A L P H A SECRETION Black Roy A; Fitzner Jeffrey N; Sleath Paul Seattle, WA, UNITED STATES Assigned to Immunex Corporation